HomeProductsBioactive CompoundsNeuronal SignalingAChRPozanicline
Chemical structure of CAS 161417-03-4

Pozanicline

In Stock•Starting at $182 for 100 mg•Purity ≥ 97%
CAS No.161417-03-4
MDL No.N/A
MFC11H16N2O
MW192.26
InChI KeyYRVIKLBSVVNSHF-JTQLQIEISA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
100 mg97%$182In Stock
250 mg97%$362In Stock
500 mg97%$552In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.161417-03-4
Product NamePozanicline
Heavy Atom Count14Rotatable Bond Count3
Atom Stereo Count1Bond Stereo Count0
HBA3HBD1
TPSA34.150 ŲCharge0
Exact Mass192.12626Complexity295.09
pKa5.875XLogP1.521

Related Articles

Studies related to this compound and its mechanism of action

Efficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study.

Psychopharmacology • Vol. 219, Issue 3 • 2012
PMID: 21748252DOI: 10.1007/s00213-011-2393-2

A randomized pilot study of the efficacy and safety of ABT-089, a novel α4β2 neuronal nicotinic receptor agonist, in adults with attention-deficit/hyperactivity disorder.

The Journal of clinical psychiatry • Vol. 73, Issue 6 • 2012
PMID: 22795204DOI: 10.4088/JCP.10m06719

Structure-activity studies of diazabicyclo[3.3.0]octane-substituted pyrazines and pyridines as potent α4β2 nicotinic acetylcholine receptor ligands.

Journal of medicinal chemistry • Vol. 54, Issue 21 • 2011
PMID: 21962147DOI: 10.1021/jm201045m

Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials.

Journal of the American Academy of Child and Adolescent Psychiatry • Vol. 50, Issue 1 • 2011
PMID: 21156272PMC: PMC3757954DOI: 10.1016/j.jaac.2010.10.001

Documentation